Lansoprazole and esomeprazole in symptomatic GERD: A double-blind, randomised, multicentre trial in 3000 patients confirms comparable symptom relief

Clinical Drug Investigation

Volumn 23, Issue 2, 2003, Pages 69-84

  Chey, William ^a,d   Huang, Bidan ^b   Jackson, Robert L ^c  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b ABBOTT LABORATORIES   (United States)

^c TAP PHARMACEUTICAL PRODUCTS INC   (United States)

^d UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; LANSOPRAZOLE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FLATULENCE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HISTORY OF MEDICINE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ONSET AGE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; VOMITING; XEROSTOMIA;

EID: 0037221527     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200323020-00001     Document Type: Article

References (21)

1. Farley A, Wruble LD, Humphries TJ. Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. Rabeprazole Study Group. Am J Gastroenterol 2000; 95: 1894-9
2. Caro JJ, Salas M, Ward A. Healing and relapse rates in gastroesophageal reflux disease treatment with newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials. Clin Ther 2001; 23: 998-1017
3. Sandmark S, Carlsson R, Fausa O, et al. Omeprazole or ranitidine in the treatment of reflux esophagitis: results of a double-blind, randomized, Scandinavian multicenter study. Scand J Gastroenterol 1988; 23: 625-32
4. Richter JE, Sabesin SM, Kogut DG, et al. Omeprazole versus ranitidine or ranitidine/metoclopramide in poorly responsive symptomatic gastroesophageal reflux disease. Am J Gastroenterol 1996; 91: 1766-72
5. Lundell L, Backman L, Ekstrom P, et al. Omeprazole or high-dose ranitidine in the treatment of patients with reflux oesophagitis not responding to 'standard doses' of H2-receptor antagonists. Aliment Pharmacol Ther 1990; 4: 145-55
6. Robinson M, Sahba B, Avner D, et al. Comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. Aliment Pharmacol Ther 1995; 9: 25-31
7. Jones RH, Baxter G, Lansoprazole 30mg daily versus ranitidine 150mg bd in the treatment of acid-related dyspepsia in general practice. Ailment Pharmacol Ther 1998; 11: 541-546
8. Gough AL, Long RG, Cooper BT, et al. Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis. Aliment Pharmacol Ther 1996; 10: 529-39
9. Winters C, Spurling TJ, Chobanian SJ, et al. Barrett's esophagus: a prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology 1987; 92: 118-24
10. Fass R, Ofman JJ. Gastroesophageal reflux disease: should we adopt a new conceptual framework? Am J Gastroenterol 2002; 97 (8): 1901-9
11. Huang JQ, Sridhar S, Hunt RH. Are there any differences in symptom relief and healing esophagitis between proton pump inhibitors: a meta-analysis of comparative trials. [Abstract.] Gut 1999; 45: P513
12. Richter JE, Kahrilas PJ, Johanson J, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001; 96: 656-65
13. Castell DO, Kahrilas PJ, Richter JE, et al. Esomeprazole (40mg) compared with lansoprazole (30mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002; 97: 575-83
14. Howden CW, Ballard D, Robieson W. Evidence of therapeutic equivalence of lansoprazole 30mg and esomeprazole 40mg in the treatment of erosive oesophagitis. Clin Drug Invest 2002; 22 (2): 99-109
15. Dohmen W, Fuchs W, Seelis REA. Onset and duration of pain relief in gastro-esophageal reflux disease (GERD): a clinical comparison of lansoprazole, omeprazole MUPS and esomeprazole [abstract]. Gastroenterology 2002; 122 Suppl. 1: A201
16. Vakil NB, Zuckerman S, Levine JG. Nocturnal heartburn in patients with erosive esophagitis and its resolution with proton pump inhibitors [abstract]. Gastroenterology 2002; 122 Suppl. 1: A200
17. Spencer CM, Faulds D. Esomeprazole. Drugs 2000; 60: 321-9
18. van Elteren PH. On the combination of independent two-sample tests of Wilcoxon. Bull Int Statis Inst 1960; 37: 351-61
19. Farup C, Kleinman L, Sloan S, et al. The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life. Arch Intern Med 2001; 161: 45-52
20. The Gallup Organization. A Gallup Organization National Survey: Understanding heartburn in America. Princeton, NJ: The Gallup Organization. May 2000
21. Richter JE, Kahrilas PJ, Sontag SJ, et al. Comparing lansoprazole and omeprazole in onset of heartburn relief: results of a randomized, controlled trial in erosive esophagitis patients. Am J Gastroenterol 2001; 96: 3089-98